Search

Your search keyword '"Takeo Hasegawa"' showing total 173 results

Search Constraints

Start Over You searched for: Author "Takeo Hasegawa" Remove constraint Author: "Takeo Hasegawa"
173 results on '"Takeo Hasegawa"'

Search Results

1. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes

2. A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

3. CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma

4. Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report

5. Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report

6. Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers

7. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature

8. The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial

9. Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles

11. Temperature analysis of aortic repair with hypothermic circulatory arrest to quantify the injury by cooling

12. Efficacy of Immune-checkpoint Inhibitors as the Peri-operative Treatment for Resectable Non-small-cell Lung Cancer

13. Improvement of predicted hematocrit values after the initiation of cardiopulmonary bypass in cardiovascular surgery

14. The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study

15. A patient with <scp>ALK</scp> ‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

16. Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)

17. Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report

19. Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report

20. CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC

21. Tumor β‑catenin expression is associated with immune evasion in non‑small cell lung cancer with high tumor mutation burden

22. Identification of short-chain pyroglutamyl peptides in Japanese salted fermented soy paste (miso) and their anti-obesity effect

23. [Monitoring Tumor Infiltrating Lymphocytes by Peripheral Blood in Lung Cancer Patients]

24. A phase 2 study of adjuvant carboplatin plus S-1 followed by maintenance S-1 therapy for patients with completely resected stage II/IIIA non-small cell lung cancer—Japanese Northern East Area Thoracic Surgery Study Group JNETS1302 study

25. Genetic alterations in epidermal growth factor receptor‑tyrosine kinase inhibitor‑na�ve non‑small cell lung carcinoma

27. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report

29. Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor

30. The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial

31. Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports

32. Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: A multi-center study of the Fukushima lung cancer association group of surgeons

33. Outcomes after surgical resection of thymic carcinoma

34. Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature

35. [Combination of Immunotherapy and Hyperthermia]

36. Prognostic impact of serum transthyretin in patients with non-small cell lung cancer

37. A case of primary pulmonary MALT lymphoma showing ground-glass nodule on chest CT

38. Can immunologically hot lung cancer be distinguished from cold tumor by peripheral blood?

39. Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer

40. Comparison of surgical outcomes after pneumonectomy and pulmonary function-preserving surgery for non-small cell lung cancer

41. P1.03-23 Delta-Like 1 Homolog (DLK1) Expression in Non-Small-Cell Lung Cancer and the Development of Radioimmunotherapy Targeting DLK1

43. [Exploring the Possibility of New Biomarkers of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer (NSCLC)]

44. [I. History of Immunotherapy and Cancer Vaccine for Lung Cancer]

45. Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination

46. Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer Patients

47. Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer

48. Prognostic Impact of FDG-PET in Surgically Treated Pathological Stage I Lung Adenocarcinoma

Catalog

Books, media, physical & digital resources